We investigated hyperpolarized [1-13C] dehydroascorbic acid (HP DHA) as an imaging agent for probing oxidative stress in patient derived xenograft models (PDXs) of pancreatic cancer. By increasing the T1 via DÂ2O solvation and increasing the dose administered via awake mouse injection, conversion of DHA to ascorbate was readily observed in BRAF and KRAS mutant cancers. HP DHA was then used to characterize oxidative stress in these PDX models and their biochemical mechanism of response to ascorbate therapy. Changes in DHA/ascorbate metabolism were measured in these tumor models, demonstrating a proof of concept method for assessing ascorbate therapy in pancreatic cancer.
This abstract and the presentation materials are available to members only; a login is required.